SG Americas Securities LLC Buys 7,117 Shares of ChromaDex Co. (NASDAQ:CDXC)

SG Americas Securities LLC increased its holdings in shares of ChromaDex Co. (NASDAQ:CDXC) by 42.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,857 shares of the company’s stock after acquiring an additional 7,117 shares during the quarter. SG Americas Securities LLC’s holdings in ChromaDex were worth $127,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of CDXC. Dimensional Fund Advisors LP bought a new position in ChromaDex during the second quarter worth about $88,000. The Manufacturers Life Insurance Company bought a new position in ChromaDex during the second quarter worth about $31,000. BSW Wealth Partners bought a new position in ChromaDex during the third quarter worth about $324,000. OneDigital Investment Advisors LLC increased its position in ChromaDex by 5.5% during the third quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock worth $217,000 after acquiring an additional 3,097 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in ChromaDex by 10.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 175,172 shares of the company’s stock worth $639,000 after acquiring an additional 17,115 shares during the period. 15.41% of the stock is owned by institutional investors.

ChromaDex Trading Down 1.8 %

NASDAQ CDXC opened at $5.50 on Wednesday. The company has a fifty day simple moving average of $5.83 and a 200 day simple moving average of $4.80. ChromaDex Co. has a 12-month low of $1.46 and a 12-month high of $7.97. The company has a market cap of $420.09 million, a P/E ratio of 550.55 and a beta of 2.21.

Analyst Ratings Changes

A number of equities analysts recently commented on CDXC shares. HC Wainwright raised their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Roth Mkm increased their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Finally, StockNews.com downgraded shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 15th.

Insider Activity at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the transaction, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. The trade was a 13.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.64% of the stock is currently owned by insiders.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.